RecruitingType 1 Diabetes
Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study
Eligible age
18+ yrs
Accepts
All genders
Locations
7 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.
Sponsor: Indiana University
You may qualify if…
- ✓ Adults ≥18 years of age
- ✓ Clinical diagnosis of T1D
- ✓ GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week
- ✓ Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study
- ✓ Willing and able to provide informed consent
You may not qualify if…
- ✕ No exclusion criteria other than those not meeting inclusion criteria above
Where it's recruiting
California
Newport Beach
Georgia
Atlanta
Illinois
Chicago
Maine
Portland
Massachusetts
Boston
Michigan
Detroit
New York
New York
Source: ClinicalTrials.gov · NCT07676565 · last updated 2026-06-30